Compare FBGL & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FBGL | ERNA |
|---|---|---|
| Founded | 1996 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.3M | 5.3M |
| IPO Year | 2022 | 2021 |
| Metric | FBGL | ERNA |
|---|---|---|
| Price | $3.65 | $3.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 929.2K | 22.2K |
| Earning Date | 04-30-2026 | 11-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $582,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.13 |
| 52 Week High | $4.30 | $15.88 |
| Indicator | FBGL | ERNA |
|---|---|---|
| Relative Strength Index (RSI) | 81.09 | 30.13 |
| Support Level | $0.51 | $0.23 |
| Resistance Level | N/A | $4.72 |
| Average True Range (ATR) | 0.20 | 0.34 |
| MACD | 0.40 | -0.06 |
| Stochastic Oscillator | 82.39 | 9.40 |
FBS Global Ltd is a green building contractor and an established interior fit-out specialist in institutional, residential, commercial, and industrial building projects. As a green contractor focused on environmentally sound practices, the company aims to bid tenders for green building projects, use green construction methods and green materials for construction projects, including design, supply, and installation of ceilings, partitions, timber deck, carpet, acoustic wall paneling, built-in furniture, as well as mechanical and electrical services of a building. The company's revenue is derived mainly from the construction contracts and sales of construction materials.
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.